Replies to post #419 on Contrafect Corp (CFRX)

[HDGabor]

s-

April 4, 2022: "We currently anticipate results from the interim futility analysis in the first half of 2022."

May 16, 2022: "we have eclipsed the enrollment threshold, meaning over 60% of the methicillin-resistant Staph aureus (MRSA) patients, needed for the interim futility analysis of our Phase 3 DISRUPT study to be conducted and we currently have about two-thirds of the entire study population enrolled as well" ... "We expect this to occur during the first week of July"

Analysis is ongoing since (as the latest) May 30 (May 16 + 14 days) ... but more likely started earlier, since app. 66% was enrolled by May 16.

Anytime ... and not later than July 15. Does Super Tuesday exist in July? :-)

Best,
G